Elon Musk Says mRNA Has 'Tremendous Promise,' Turning Disease Into a 'Software Problem,' as Moderna Stock Rockets 177% on Cancer Vaccine Breakthrough
Key takeaways
- Moderna and Merck’s Phase 3 melanoma vaccine win validates mRNA oncology, sending shares soaring and boosting confidence in the platform’s future.
- Moderna shares up 176.97% to $174.38
- Merck shares up 12.6% to $152.20
- BioNTech gained 21.96% to $113.12
What happened
Moderna Inc. (NASDAQ: MRNA) and Merck & Co. (NYSE: MRK) announced positive Phase 3 results for an individualized mRNA cancer vaccine that improves recurrence‑free and metastasis‑free survival in melanoma patients when combined with Merck’s Keytruda. The trial is the first successful late‑stage study of its kind, and the news sent Moderna’s shares up 176.97% to $174.38 before a 4.65% after‑hours pullback. Merck’s stock rose 12.6% to $152.20. Elon Musk praised mRNA as a “software problem” for…
Why it matters
The trial demonstrates that personalized mRNA vaccines can achieve clinically meaningful outcomes in solid tumors, validating the platform’s therapeutic potential beyond COVID‑19. It positions Moderna and Merck as leaders in oncology immunotherapy, potentially expanding their product pipelines and revenue streams.…
Short-term and longer-term
Short-term. Moderna’s shares spiked 177% on the news, indicating a strong short‑term upside.
Longer-term. The trial confirms mRNA’s viability in oncology, potentially expanding Moderna’s and Merck’s product pipelines and revenue streams over the next 12–24 months.